Drug Details
| General Information of the Drug (ID: DR2116) | ||||
|---|---|---|---|---|
| Name |
Lonidamine
|
|||
| Synonyms |
lonidamine; 50264-69-2; 1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid; Diclondazolic acid; Doridamina; DICA; Lonidamina; Lonidaminum; Lonidamin; AF 1890; 1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid; 1-(2,4-Dichlorbenzyl)-indazole-3-carboxylic acid; UNII-U78804BIDR; C15H10Cl2N2O2; 1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid; 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid; AF-1890; MLS000028822; U78804BIDR; CHEBI:50138; 1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-; AF-1890;Diclondazolic Acid;DICA; MFCD00866285; NCGC00015609-03; SMR000058467; DSSTox_CID_782; DSSTox_RID_75787; DSSTox_GSID_20782; Lonidaminum [INN-Latin]; Lonidamina [INN-Spanish]; Doridamina (TN); Dichlondazolic acid; Lonidamine (INN); CAS-50264-69-2; CCRIS 3516; Lonidamine [INN:BAN]; SR-01000075961; EINECS 256-510-0; BRN 0894483; KN-228; TH-070; Tocris-1646; Lopac-L-4900; L 4900; SCHEMBL7134; Lopac0_000718; cid_39562; ZINC1632; CHEMBL1257030; DTXSID5020782; BDBM59775; 1H-Indazole-3-carboxylic acid, 1-(2,4-dichlorobenzyl)-; HMS2234H24; HMS3262O17; HMS3268K09; HMS3369I01; HMS3412P05; HMS3651F09; HMS3676P05; HMS3874D03; Pharmakon1600-01503225; 1H-Indazole-3-carboxylicacid, 1-[(2,4-dichlorophenyl)methyl]-; ACT02617; BCP06555; HY-B0486; Tox21_110181; Tox21_202306; Tox21_500718; NSC741419; NSC758419; s2610; AKOS012842739; Tox21_110181_1; AC-5626; CCG-204803; DB06266; LP00718; NSC 741419; NSC 758419; NSC-741419; NSC-758419; SDCCGSBI-0050696.P003; NCGC00015609-01; NCGC00015609-02; NCGC00015609-04; NCGC00015609-05; NCGC00015609-06; NCGC00015609-07; NCGC00015609-08; NCGC00015609-09; NCGC00015609-16; NCGC00025244-01; NCGC00025244-02; NCGC00025244-03; NCGC00259855-01; NCGC00261403-01; AS-11653; SBI-0050696.P002; AB0010495; AM20060642; EU-0100718; FT-0650359; SW219810-1; Lonidamine, mitochondrial hexokinase inhibitor; D07257; J90044; S-4929; AB00597141_08; AB00597141_10; 264L692; Q-201318; Q3836670; SR-01000075961-1; SR-01000075961-3; SR-01000075961-6; BRD-K78513633-001-03-3; BRD-K78513633-001-06-6; Z1741977188; 1-[(2,4-dichlorophenyl)methyl]-3-indazolecarboxylic acid; 1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)- (9CI)
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Prostate hyperplasia [ICD-11: GA90] | Discontinued in Phase 3 | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C15H10Cl2N2O2
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O
|
|||
| InChI |
1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21)
|
|||
| InChIKey |
WDRYRZXSPDWGEB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 50264-69-2
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
| RPMI-8866 | CVCL_1668 | Chronic myelogenous leukemia | Homo sapiens | |||
| Experimental
Result(s) |
lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes. | |||||
